预约演示
更新于：2026-02-10
Paclitaxel
紫杉醇
更新于：2026-02-10
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C47H51NO14 |
InChIKeyRCINICONZNJXQF-MZXODVADSA-N |
CAS号33069-62-4 |
关联
2,862
项与 紫杉醇 相关的临床试验NCT07346196
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
NCT07195734
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
NCT05411237
A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings
100 项与 紫杉醇 相关的临床结果
登录后查看更多信息
100 项与 紫杉醇 相关的转化医学
登录后查看更多信息
100 项与 紫杉醇 相关的专利（医药）
登录后查看更多信息
49,027
项与 紫杉醇 相关的文献（医药）2026-12-31Future Science OA
Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer
Article
作者: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana
OBJECTIVE:
We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.
METHODS:
The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.
RESULT:
A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.
CONCLUSION:
The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.
2026-12-31DRUG DELIVERY
The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity
Article
作者: Jiang, Chengwei ; Schätzlein, Andreas G. ; Uchegbu, Ijeoma F. ; Xiong, Guojun
Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (α-helix = 17%) is structurally denatured compared with native HSA (α-helix = 68%), leading to rapid clearance (<1 h) from the circulation and that drug loading is driven by pharmaceutical HSA's amphiphilicity rather than by its hydrophobic pockets. Here, we revealed that Nab-PTX is composed of protein-coated PTX solid cores. These nanosystems have insufficient surface charge (ζ = -13.7 mV), leading to aggregation, and low colloidal stability, resulting in premature drug release upon dilution (<0.1 mg/mL). To address these shortcomings, we developed HSA-polylactic acid (HSA-PLA) nanoparticles with enhanced negative surface charge (ζ = -27.4 mV) and improved colloidal stability to reduce the premature release of encapsulated PTX upon dilution (<0.01 mg/mL). In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 µg·h/g, p < 0.01) and superior antitumor efficacy compared with Abraxane. These improvements further suggest that optimization may require only a simple modification when guided by proper theoretical principles.
2026-12-31Molecular & Cellular Oncology
SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration
Article
作者: Chen, Ping ; Li, Pin ; Wang, Lei ; Wen, Kailing ; Yu, Xiaoyan ; Yu, Jingran
Sorting nexin 1 (SNX1), a member of the sorting nexin family, has been implicated in various cellular processes, yet its role in ovarian cancer (OV) remains poorly characterized. In this study, we systematically investigated the expression pattern, prognostic relevance and functional impact of SNX1 in OV. Bioinformatics analysis revealed that SNX1 is significantly downregulated in OV tissues, and its low expression is associated with poor overall and progression-free survival. Gene set enrichment analysis indicated that SNX1 downregulation is linked to activation of cancer-related pathways, including p53 signaling, PI3K/AKT signaling, and cell cycle-associated programs such as E2F targets and G2/M checkpoint. Functionally, SNX1 overexpression inhibited OV cell proliferation, blocked G1/S transition (with downregulation of E2F1, CDK2, CDK6, and cyclin D1), promoted apoptosis, and suppressed cell migration by modulating EMT markers (upregulating E-cadherin; downregulating N-cadherin, vimentin, Snail1, and β-catenin). Drug sensitivity analysis demonstrated a synergistic anti-tumor effect between SNX1 overexpression and paclitaxel treatment. Collectively, our findings identify SNX1 as a tumor suppressor and potential therapeutic target in OV, functioning through regulation of cell cycle, apoptosis and migration.
100 项与 紫杉醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期胃癌 | 中国 | 2024-09-19 | |
| 晚期胃癌 | 中国 | 2024-09-19 | |
| 转移性胰腺腺癌 | 欧盟 | 2024-01-05 | |
| 转移性胰腺腺癌 | 冰岛 | 2024-01-05 | |
| 转移性胰腺腺癌 | 列支敦士登 | 2024-01-05 | |
| 转移性胰腺腺癌 | 挪威 | 2024-01-05 | |
| 铂类耐药性原发性腹膜癌 | 欧盟 | 2018-11-20 | |
| 铂类耐药性原发性腹膜癌 | 冰岛 | 2018-11-20 | |
| 铂类耐药性原发性腹膜癌 | 列支敦士登 | 2018-11-20 | |
| 铂类耐药性原发性腹膜癌 | 挪威 | 2018-11-20 | |
| 铂敏感性卵巢上皮癌 | 欧盟 | 2018-11-20 | |
| 铂敏感性卵巢上皮癌 | 冰岛 | 2018-11-20 | |
| 铂敏感性卵巢上皮癌 | 列支敦士登 | 2018-11-20 | |
| 铂敏感性卵巢上皮癌 | 挪威 | 2018-11-20 | |
| 铂敏感性输卵管癌 | 欧盟 | 2018-11-20 | |
| 铂敏感性输卵管癌 | 冰岛 | 2018-11-20 | |
| 铂敏感性输卵管癌 | 列支敦士登 | 2018-11-20 | |
| 铂敏感性输卵管癌 | 挪威 | 2018-11-20 | |
| 生殖细胞瘤 | 日本 | 2013-02-21 | |
| 生殖细胞瘤 | 日本 | 2013-02-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胰腺癌 | 申请上市 | 欧盟 | 2023-11-09 | |
| 转移性胰腺癌 | 临床3期 | 中国 | 2025-01-21 | |
| 高级别胶质瘤 | 临床3期 | 中国 | 2024-04-01 | |
| HEGF2阴性乳腺癌 | 临床3期 | 中国 | 2023-09-25 | |
| 皮肤鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 下咽癌 | 临床3期 | 美国 | 2023-06-08 | |
| 转移性头颈部鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 下咽部鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 喉鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 口腔鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 26 | 襯選餘鬱餘齋鹹鑰膚鹽 = 糧襯鏇遞廠顧網鹹夢廠 簾獵糧壓艱獵鹹鹽淵壓 (襯鹹鏇淵醖選範獵餘醖, 鏇築蓋鬱壓衊鹽鹽淵構 ~ 構鑰選衊壓襯鏇窪醖廠) 更多 | - | 2026-01-22 | |||
临床2期 | 442 | Biopsy Arm A+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 840 MG in 14 ML Injection+epirubicin (Arm A) | 鹽遞醖繭鹽顧醖餘觸齋 = 繭網壓鏇構願艱鹽鬱壓 鑰壓鏇艱蓋廠蓋獵窪淵 (餘夢鹽構艱鏇膚膚壓餘, 觸鹹鏇憲襯築範淵鹹衊 ~ 淵鹽範衊衊鏇顧鹽淵淵) 更多 | - | 2026-01-12 | ||
Biopsy Arm B+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 1200 MG in 20 ML Injection+epirubicin (Arm B) | 鹽遞醖繭鹽顧醖餘觸齋 = 憲願鹽製鏇鑰鹽願鏇構 鑰壓鏇艱蓋廠蓋獵窪淵 (餘夢鹽構艱鏇膚膚壓餘, 膚積餘獵範鬱衊淵糧顧 ~ 獵蓋築繭糧鑰廠願壓獵) 更多 | ||||||
临床2期 | 胃癌 新辅助 | 201 | 廠範糧壓襯鑰艱廠鹹範(夢鑰餘簾餘簾艱願鑰繭) = 淵願構選鹽製鹹獵餘遞 鬱顧廠遞遞鹽窪繭糧觸 (餘鹽醖選夢製鬱積膚齋, 58 ~ 80) 更多 | 积极 | 2026-01-08 | ||
廠範糧壓襯鑰艱廠鹹範(夢鑰餘簾餘簾艱願鑰繭) = 醖構襯獵艱蓋繭構鬱築 鬱顧廠遞遞鹽窪繭糧觸 (餘鹽醖選夢製鬱積膚齋, 75 ~ 94) 更多 | |||||||
临床2期 | 29 | FTD-TPI+RAM | 窪夢獵簾夢鬱鬱繭願廠(願構製製構構構窪網鏇) = 積構窪襯壓鹹膚淵鏇築 艱積膚構艱構夢淵獵範 (糧鏇觸獵憲遞製鏇壓膚 ) 更多 | 不佳 | 2026-01-08 | ||
PAC+RAM | 窪夢獵簾夢鬱鬱繭願廠(願構製製構構構窪網鏇) = 網遞蓋廠艱觸醖獵築製 艱積膚構艱構夢淵獵範 (糧鏇觸獵憲遞製鏇壓膚 ) 更多 | ||||||
临床2期 | 腹膜癌 巩固 | 31 | IP PTX + systemic therapy | 艱衊簾夢襯餘壓網醖顧(醖餘襯製範鹹築襯鹽顧) = 窪顧顧鏇觸築蓋鏇糧夢 壓醖願夢齋糧網鹽鏇構 (獵齋鹽選膚鬱範淵膚淵 ) 更多 | 积极 | 2026-01-08 | |
临床3期 | 190 | (Arm I (Pertuzumab, Trastuzumab, Taxane Therapy, Placebo)) | 製築構鏇襯繭觸餘衊憲 = 廠製範簾簾憲蓋構廠築 醖築廠餘廠衊憲鏇觸願 (餘艱襯鹹襯糧夢製夢衊, 築積膚積齋蓋憲選選簾 ~ 簾觸艱膚窪艱遞簾鬱窪) 更多 | - | 2025-12-30 | ||
(Arm II (Pertuzumab, Trastuzumab, Taxane Therapy, Atezolizumab)) | 製築構鏇襯繭觸餘衊憲 = 繭餘鹹艱齋願顧廠艱鏇 醖築廠餘廠衊憲鏇觸願 (餘艱襯鹹襯糧夢製夢衊, 夢醖淵觸鏇壓憲衊餘簾 ~ 憲襯憲遞廠壓簾繭獵鹽) 更多 | ||||||
临床1期 | 25 | (DL1 Dose Escalation Cohort) | 糧鹽憲蓋窪範顧鑰簾鹹 = 糧夢餘積憲獵夢醖網鹹 觸鑰積鬱廠艱觸窪繭築 (襯繭網願壓壓餘蓋齋積, 餘壓夢網壓糧鬱製憲淵 ~ 襯繭鑰構鏇齋齋夢鬱鑰) 更多 | - | 2025-12-19 | ||
(DL2 Dose Escalation Cohort) | 糧鹽憲蓋窪範顧鑰簾鹹 = 鹽壓簾鑰蓋願願遞範觸 觸鑰積鬱廠艱觸窪繭築 (襯繭網願壓壓餘蓋齋積, 艱憲鹽憲顧製構衊鹹簾 ~ 簾願顧製製顧繭醖範鏇) 更多 | ||||||
临床2期 | 20 | (Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT)) | 積製憲淵餘蓋範構積艱 = 壓簾鑰鏇壓夢蓋顧選齋 遞獵醖廠醖網顧鬱積壓 (鏇襯憲廠網範醖繭鑰選, 艱簾獵顧淵蓋蓋網鬱繭 ~ 網鹹鏇窪膚餘憲鑰鹹製) 更多 | - | 2025-11-25 | ||
(Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT)) | 積製憲淵餘蓋範構積艱 = 願獵顧蓋繭鏇構製鏇膚 遞獵醖廠醖網顧鬱積壓 (鏇襯憲廠網範醖繭鑰選, 範鏇鑰願窪窪膚積夢範 ~ 鏇艱範觸齋鹽壓範糧餘) 更多 | ||||||
临床2期 | 21 | (Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel)) | 餘壓餘範簾襯艱願醖艱(衊簾襯繭衊鹹糧艱獵鏇) = 膚顧範鹹淵選鹽壓製網 齋鹹構構簾壓鏇廠艱網 (鏇襯憲築壓糧鬱製簾鏇, 餘膚襯窪糧淵廠壓網淵 ~ 糧遞壓範構壓夢製築積) 更多 | - | 2025-10-30 | ||
(Active Comparator: Arm B (Carboplatin, Paclitaxel)) | 餘壓餘範簾襯艱願醖艱(衊簾襯繭衊鹹糧艱獵鏇) = 膚獵鑰網鹹願鏇壓憲網 齋鹹構構簾壓鏇廠艱網 (鏇襯憲築壓糧鬱製簾鏇, 構鬱糧築顧鑰憲鹽獵膚 ~ 構鏇顧願鑰廠淵鹽鹽積) 更多 | ||||||
临床2期 | 10 | 築蓋鏇顧夢齋艱構範構 = 繭糧襯鏇醖糧壓積簾願 積選襯鑰憲夢蓋蓋觸繭 (願網憲夢糧積遞鑰願鹹, 鑰鬱夢壓餘願鏇憲蓋範 ~ 獵築鹽繭糧膚築醖廠衊) 更多 | - | 2025-10-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用